Yanan Zhu
Stock Analyst at Wells Fargo
(0.82)
# 3,736
Out of 4,761 analysts
60
Total ratings
23.91%
Success rate
-16.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Overweight | $70 → $60 | $12.17 | +393.02% | 3 | Jan 10, 2025 | |
| AFMD Affimed | Maintains: Overweight | $20 → $15 | $1.04 | +1,342.31% | 6 | Dec 12, 2024 | |
| EDIT Editas Medicine | Downgrades: Equal-Weight | $7 → $4 | $1.92 | +108.33% | 6 | Dec 11, 2024 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $17 → $4 | $1.25 | +220.00% | 4 | Nov 12, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $82 → $77 | $32.32 | +138.24% | 2 | Nov 7, 2024 | |
| BLUE bluebird bio | Maintains: Equal-Weight | $60 → $40 | $4.08 | +880.39% | 7 | Sep 25, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Overweight | $35 → $40 | $21.29 | +87.88% | 2 | May 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $70 → $65 | $47.91 | +35.67% | 1 | May 9, 2024 | |
| ENGN enGene Holdings | Initiates: Overweight | $30 | $6.29 | +376.95% | 1 | Apr 22, 2024 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $45 → $58 | $17.77 | +226.39% | 5 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $2.36 | +959.32% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $25 | $5.78 | +332.53% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $31.12 | +60.67% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $14 | $4.22 | +231.75% | 1 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $1.42 | +252.11% | 2 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $1.07 | +273.83% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $1.68 | +26,685.71% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $8 | $1.95 | +310.26% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $105 | $30.43 | +245.05% | 2 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $10 | $1.61 | +521.12% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1.5 → $3 | $0.56 | +436.19% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $34 → $24 | $12.84 | +86.92% | 1 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $644.48 | -49.42% | 1 | Feb 2, 2021 |
Intellia Therapeutics
Jan 10, 2025
Maintains: Overweight
Price Target: $70 → $60
Current: $12.17
Upside: +393.02%
Affimed
Dec 12, 2024
Maintains: Overweight
Price Target: $20 → $15
Current: $1.04
Upside: +1,342.31%
Editas Medicine
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $7 → $4
Current: $1.92
Upside: +108.33%
RAPT Therapeutics
Nov 12, 2024
Maintains: Overweight
Price Target: $17 → $4
Current: $1.25
Upside: +220.00%
Ionis Pharmaceuticals
Nov 7, 2024
Maintains: Overweight
Price Target: $82 → $77
Current: $32.32
Upside: +138.24%
bluebird bio
Sep 25, 2024
Maintains: Equal-Weight
Price Target: $60 → $40
Current: $4.08
Upside: +880.39%
Spyre Therapeutics
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $21.29
Upside: +87.88%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $47.91
Upside: +35.67%
enGene Holdings
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $6.29
Upside: +376.95%
Arcturus Therapeutics Holdings
Mar 8, 2024
Maintains: Overweight
Price Target: $45 → $58
Current: $17.77
Upside: +226.39%
Mar 5, 2024
Initiates: Overweight
Price Target: $25
Current: $2.36
Upside: +959.32%
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $5.78
Upside: +332.53%
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $31.12
Upside: +60.67%
Jan 2, 2024
Upgrades: Overweight
Price Target: $9 → $14
Current: $4.22
Upside: +231.75%
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.42
Upside: +252.11%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $1.07
Upside: +273.83%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $1.68
Upside: +26,685.71%
Mar 27, 2023
Assumes: Overweight
Price Target: $8
Current: $1.95
Upside: +310.26%
Mar 1, 2023
Maintains: Overweight
Price Target: $125 → $105
Current: $30.43
Upside: +245.05%
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $1.61
Upside: +521.12%
Nov 14, 2022
Maintains: Equal-Weight
Price Target: $1.5 → $3
Current: $0.56
Upside: +436.19%
Aug 9, 2022
Maintains: Equal-Weight
Price Target: $34 → $24
Current: $12.84
Upside: +86.92%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $644.48
Upside: -49.42%